hema.to, a Munich, Germany-based health tech bringing AI automation to the clinical analysis of blood data, has raised a €3.6 million seed funding round backed by Elaia Partners, Heal Capital, and High-Tech Gründerfonds (HTGF).
The funds will allow the company to grow its team of software engineers and immunologists/cytometrists, and scale its AI capabilities.
hema.to will use the fresh funding to grow its team of software engineers and immunologists, and scale its AI capabilities
The analysis of blood data, known as Cytometr, is a time-consuming exercise, coupled with shortages in laboratory staff there was much scope for the system to be improved upon. hema.to wants to improve the system by using its cloud-based machine learning platform to personalize the analysis and bring ‘precision diagnostics to immune medicine’.
“Europe’s largest leukemia lab had the real need to speed-up their internal analysis workflows and worked with us to build a world-first AI prototype. After the success of demonstration of AI-assisted clinical cytometry, we noticed that all labs have the same manual workflows and pain points. We founded hema.to two years ago to help labs across the world with their clinical cytometry workflows,” says Karsten Miermans, co-founder and CEO of hema.to.
Company: hema.to GmbH
Round: Seed Round
Funding Month: June 2023
Lead Investors: Elaia Partners, Heal Capital, and High-Tech Gründerfonds (HTGF)
Company Website: https://www.hema.to/
Software Category: Decision Support Software
About the Company: Founded in 2019, hema.to is a medtech company that provides fully automated, AI-powered diagnosis recommendations for blood cancer from flow cytometry data. hema.to uses AI to help diagnosticians assess blood cancer and other immune diseases from immune data (”flow cytometry” or “immunophenotyping”). The company empowers hematology labs to increase efficiency while maintaining quality.